Clinical events following transplantation
| Clinical events . | Group 1: Patients receiving HBsAg-positive marrow (n = 18) . | Group 2: Patients receiving HBsAg-negative marrow (n = 18) . |
|---|---|---|
| Hepatitis | 14* (8) | 8 (2) |
| Acute/chronic | 9 (3)/5 (5) | 7 (2)/1 (0) |
| Anicteric/icteric/hepatic failure | 7 (2)/1 (0)/6 (6*) | 4 (2)/4 (0)/0 (0*) |
| Cause of hepatitis | ||
| HBV-related | 8 | 2 |
| Serological clearance of HBsAg and/or HBeAg | 0* | 4 |
| Relapse | 1 | 0 |
| Infection | 3 | 1 |
| Drug-related | 0 | 0 |
| Cause undetermined | 2 | 1 |
| Hepatic graft-versus-host disease: | 7 | 5 |
| Grade 1/2/3/4 | 3/3/0/1 | 3/1/0/1 |
| Veno-occlusive disease | 14 | 10 |
| Mild/moderate/severe | 6/7/1 | 6/4/0 |
| Cause of death | ||
| Hepatic failure | 4 (4) | 0 |
| Relapse | 4 | 2 |
| Infection | 3 | 2 |
| Total number of deaths | 11* (4) | 4 (0) |
| Clinical events . | Group 1: Patients receiving HBsAg-positive marrow (n = 18) . | Group 2: Patients receiving HBsAg-negative marrow (n = 18) . |
|---|---|---|
| Hepatitis | 14* (8) | 8 (2) |
| Acute/chronic | 9 (3)/5 (5) | 7 (2)/1 (0) |
| Anicteric/icteric/hepatic failure | 7 (2)/1 (0)/6 (6*) | 4 (2)/4 (0)/0 (0*) |
| Cause of hepatitis | ||
| HBV-related | 8 | 2 |
| Serological clearance of HBsAg and/or HBeAg | 0* | 4 |
| Relapse | 1 | 0 |
| Infection | 3 | 1 |
| Drug-related | 0 | 0 |
| Cause undetermined | 2 | 1 |
| Hepatic graft-versus-host disease: | 7 | 5 |
| Grade 1/2/3/4 | 3/3/0/1 | 3/1/0/1 |
| Veno-occlusive disease | 14 | 10 |
| Mild/moderate/severe | 6/7/1 | 6/4/0 |
| Cause of death | ||
| Hepatic failure | 4 (4) | 0 |
| Relapse | 4 | 2 |
| Infection | 3 | 2 |
| Total number of deaths | 11* (4) | 4 (0) |
Parentheses indicate HBV-related.
P value of the difference <.05.